RP-3 by Replimune for Gastrointestinal Tract Cancer: Likelihood of Approval

Grit­stone bio will get up to $433 mil­lion from the US gov­ern­ment to run a Phase IIb tri­al ear­ly next year test­ing its self-am­pli­fy­ing mR­NA

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it